Insider buying
~$1.1K2,500 sh @ $0.42
9 days before an 8-KTraded Dec 15, 2025 · filed 1 day later
The CEO of Silo Pharma paid $1.1K out of pocket for Silo Pharma shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 19, 2025 · Filed Nov 20, 2025
The CEO of Silo Pharma paid $1.8K out of pocket for Silo Pharma shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$1,823
Shares × reported transaction price
<$25K
+2.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Eric Weisblum, Chief Executive Officer's past purchases, 90 days after disclosure: 6 buys, median +3.6 pts vs S&P 500, beat it 3 of 6 times. Past results, not a forecast.
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 1 earlier confirmed purchase
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2024 ($630K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-06-30. The proxy does not tag the CEO's name, so the match rests on the Form 4 title only. A size comparison, not a judgement
Closed at $5.93 on Nov 19, 2025, at its 52-week low, after a 43% drop over the previous 30 trading days
52-week range $5.93 (Nov 19, 2025) to $29.70 (Jan 16, 2025), 0% of the way up, from 250 adjusted closes. 30 trading days earlier: $10.39 on Oct 8, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +19.2% | +3.7% | +15.5% |
| 30 days | +10.2% | +3.9% | +6.3% |
| 90 days | −24.4% | +3.9% | −28.3% |
| 180 days | −4.6% | +12.5% | −17.0% |
Past results only. Not a forecast.
Insider buying
9 days before an 8-KTraded Dec 15, 2025 · filed 1 day later
The CEO of Silo Pharma paid $1.1K out of pocket for Silo Pharma shares.
Insider buying
9 days before an 8-KTraded Dec 15, 2025 · filed 1 day later
The CEO of Silo Pharma paid $1K out of pocket for Silo Pharma shares.
Insider buying
Traded Nov 20, 2025 · filed 1 day later
The CEO of Silo Pharma paid $370 out of pocket for Silo Pharma shares.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.